Skip to main content
. Author manuscript; available in PMC: 2022 Nov 1.
Published in final edited form as: Neuropharmacology. 2022 Aug 22;218:109233. doi: 10.1016/j.neuropharm.2022.109233

Fig. 7. The CNS safety assessments of ELB00824.

Fig. 7.

(A and B) The effect of ELB00824 on motor coordination/sedation evaluated by means of beam traversal test, and bars are beam walking latency A in sec) and number of errors (B) committed for the animals (n = 6/group), 2 h after i.p. injection of Veh (DMSO/Cremophor vehicle), Carb 30 (30 mg/kg of carbamazepine), ELB 10, ELB 30, ELB 60, ELB 90, or ELB 120 (10, 30, 60,90, 120 mg/kg of ELB00824, respectively). The box-and-whiskers plots show minimum, maximum, median and 25th and 75th percentiles. Inter-group comparison used one-way ANOVA, followed by Dunn’s test. *: p < 0.05; **: p < 0.01 vs Veh group. (C and D) The effect of ELB00824 on addiction evaluated by conditioned place preference. To pair the drug with one of two distinct contexts, each group was assigned a ‘side’ of the addiction box: striped (C) or blank (D), and scatter plots are time spent (in min, mean ± SD, n = 3/group) in the drug-paired compartment in the pre-conditioning (pre) and the post-conditioning (post) test sessions on each group on the 2nd day after 3 consecutive daily i.p. injections of either Veh (DMSO/Cremophor vehicle), Mor (5 mg/kg of morphine), ELB 30 (30 mg/kg of ELB00824), or ELB 60 (60 mg/kg of ELB00824). ***p < 0.001.